Nanotechnology for CAR T cells and tumour-infiltrating lymphocyte therapies
Source abstract
Abstract
Adoptive T-cell therapies, and particularly CAR T cells and tumour-infiltrating lymphocytes, have transformed cancer treatment by selectively targeting malignant cells. Despite their clinical success, these therapies face substantial challenges, including costly manufacturing processes and tumour-imposed barriers that limit efficacy. Advances in understanding the nanoscale mechanisms governing T-cell activation and the role of the tumour microenvironment in restricting T-cell responses have driven the development of nanotechnology-based strategies that integrate key chemical and physical cues. Here we provide a brief overview of the current state of CAR T and tumour-infiltrating lymphocyte therapies and discuss nanotechnology strategies to enhance their ex vivo production, in vivo performance and the direct in vivo generation of CAR T cells. We highlight nanotechnology's transformative potential to overcome existing challenges, broaden therapeutic applications and identify factors that will shape the future of nanotechnology for CAR T and tumour-infiltrating lymphocyte therapies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: CAR-T cell therapy research · Nanowire Synthesis and Applications · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Emens, L. A. et al. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J. Immunother. Cancer 12, e009063 (2024).10.1136/jitc-2024-009063 ↗
2. Atkins, M., Kunkel, L., Sznol, M. & Rosenberg, S. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6, 11–14 (2000).
3. Yang, J. C. et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127–3132 (2003).10.1200/JCO.2003.02.122 ↗
4. He, X. & Xu, C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 30, 660–669 (2020).10.1038/s41422-020-0343-4 ↗
5. Irvine, D. J., Maus, M. V., Mooney, D. J. & Wong, W. W. The future of engineered immune cell therapies. Science 378, 853–858 (2022).10.1126/science.abq6990 ↗
6. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).10.1126/science.aaa4967 ↗
7. Awasthi, R., Maier, H. J., Zhang, J. & Lim, S. Kymriah® (tisagenlecleucel)–An overview of the clinical development journey of the first approved CAR-T therapy. Hum. Vaccin. Immunother. 19, 2210046 (2023).10.1080/21645515.2023.2210046 ↗
8. Julve, M., Lythgoe, M. P., Larkin, J. & Furness, A. J. S. Lifileucel: the first cellular therapy approved for solid tumours. Trends Cancer 10, 475–477 (2024).10.1016/j.trecan.2024.04.003 ↗
9. Monberg, T. J., Borch, T. H., Svane, I. M. & Donia, M. TIL therapy: facts and hopes. Clin. Cancer Res. 29, 3275–3283 (2023).10.1158/1078-0432.CCR-22-2428 ↗
10. Liu, Y., Sperling, A. S., Smith, E. L. & Mooney, D. J. Optimizing the manufacturing and antitumour response of CAR T therapy. Nat. Rev. Bioeng. 1, 271–285 (2023).10.1038/s44222-023-00031-x ↗
11. Matsueda, S., Chen, L., Li, H., Yao, H. & Yu, F. Recent clinical researches and technological development in TIL therapy. Cancer Immunol. Immunother. 73, 232 (2024).10.1007/s00262-024-03793-4 ↗
12. Hyun, J., Kim, S. J., Cho, S. D. & Kim, H. W. Mechano-modulation of T cells for cancer immunotherapy. Biomaterials 297, 122101 (2023).10.1016/j.biomaterials.2023.122101 ↗
13. Wang, F. Y., Qiu, T., Ling, Y., Yang, Y. & Zhou, Y. Physical and chemical cues at the nano–bio interface for immunomodulation. Angew. Chem. 61, e202209499 (2022).10.1002/anie.202209499 ↗
14. Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720–724 (1993).10.1073/pnas.90.2.720 ↗
15. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).10.1126/scitranslmed.3002842 ↗
16. FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. US Food and Drug Administration https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute (2024).
17. Juan, M., Delgado, J., Calvo, G., Trias, E. & Urbano-Ispizua, Á. Is hospital exemption an alternative or a bridge to european medicines agency for developing academic chimeric antigen receptor T-cell in Europe? Our experience with ARI-0001. Hum. Gene Ther. 32, 1004–1007 (2021).10.1089/hum.2021.168 ↗
18. Damodar, S. et al. Early results from a phase-2 study of varnimcabtagene autoleucel (IMN-003A), a first-in-India industry CD19-directed CAR-T cell therapy with fractionated infusions for patients with relapsed and/or refractory B cell malignancies (IMAGINE study). Blood 140, 10343–10344 (2022).10.1182/blood-2022-166297 ↗
19. Oliver-Caldes, A. et al. Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma. Clin. Cancer Res. 30, 2085–2096 (2024).10.1158/1078-0432.CCR-23-3759 ↗
20. Nie, T. Talicabtagene autoleucel: first approval. Mol. Diagn. Ther. 28, 495–499 (2024).10.1007/s40291-024-00719-9 ↗
21. Therapeutics announces NMPA approval of the supplemental biological license application for Carteyva in adult patients with relapsed or refractory mantle cell lymphoma. JW Therapeutics https://www.jwtherapeutics.com/en/media/press-release/20240827/ (2024).
22. Wang, Y. et al. Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia. Blood Adv. 9, 836–843 (2025).10.1182/bloodadvances.2024014182 ↗
23. Saez-Ibañez, A. R. et al. The changing landscape of cancer cell therapies: clinical trials and real-world data. Nat. Rev. Drug Discov. 23, 736–737 (2024).10.1038/d41573-024-00094-4 ↗
24. Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318–1321 (1986).10.1126/science.3489291 ↗
25. Diorio, C., Teachey, D. T. & Grupp, S. A. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat. Rev. Clin. Oncol. 22, 10–27 (2025).10.1038/s41571-024-00959-y ↗
26. Hopewell, E. L., Cox, C., Pilon-Thomas, S. & Kelley, L. L. Tumor infiltrating lymphocytes streamlining a complex manufacturing process. Cytotherapy 21, 307–314 (2018).10.1016/j.jcyt.2018.11.004 ↗
27. Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat. Rev. Clin. Oncol. 20, 49–62 (2022).10.1038/s41571-022-00704-3 ↗
28. Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47–66 (2023).10.1038/s41571-023-00832-4 ↗
29. Zhao, Y. et al. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers 14, 4160 (2022).10.3390/cancers14174160 ↗
30. Madkour, L. H. in Nanoelectronic Materials: Fundamentals and Applications (ed. Madkour, L. H.) 1–47 (Springer, 2019).10.1007/978-3-030-21621-4_1 ↗
31. Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101–124 (2020).10.1038/s41573-020-0090-8 ↗
32. Joyce, P. et al. A translational framework to DELIVER nanomedicines to the clinic. Nat. Nanotechnol. 19, 1597–1611 (2024).10.1038/s41565-024-01754-7 ↗
33. Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic: an update post COVID-19 vaccines. Bioeng. Transl. Med. 6, e10246 (2021).10.1002/btm2.10246 ↗
34. Hou, F., Guo, Z., Ho, M. T., Hui, Y. & Zhao, C. X. Particle-based artificial antigen-presenting cell systems for T cell activation in adoptive T cell therapy. ACS Nano 18, 8571–8599 (2024).10.1021/acsnano.3c10180 ↗
35. Hu, T., Kumar, A. R. K., Luo, Y. & Tay, A. Automating CAR-T transfection with micro and nano-technologies. Small Methods 8, e2301300 (2024).10.1002/smtd.202301300 ↗
36. Sunshine, J. C. & Green, J. J. Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine 8, 1173–1189 (2013).10.2217/nnm.13.98 ↗
37. Dahotre, S. N., Romanov, A. M., Su, F. Y. & Kwong, G. A. Synthetic antigen-presenting cells for adoptive T cell therapy. Adv. Ther. 4, 2100034 (2021).10.1002/adtp.202100034 ↗
38. Ben-Akiva, E. et al. Shape matters: biodegradable anisotropic nanoparticle artificial antigen presenting cells for cancer immunotherapy. Acta Biomater. 160, 187–197 (2023).10.1016/j.actbio.2023.02.023 ↗
39. Perica, K. et al. Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine 10, 119–129 (2014).10.1016/j.nano.2013.06.015 ↗
40. Isser, A. et al. Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy. Nat. Commun. 13, 6086 (2022).10.1038/s41467-022-33597-y ↗
41. Ichikawa, J. et al. Rapid expansion of highly functional antigen-specific T cells from patients with melanoma by nanoscale artificial antigen-presenting cells. Clin. Cancer Res. 26, 3384–3396 (2020).10.1158/1078-0432.CCR-19-3487 ↗
42. Lee, K. & Yu, Y. Janus nanoparticles for T cell activation: clustering ligands to enhance stimulation. J. Mater. Chem. B 5, 4410–4415 (2017).10.1039/C7TB00150A ↗
43. Matic, J., Deeg, J., Scheffold, A., Goldstein, I. & Spatz, J. P. Fine tuning and efficient T cell activation with stimulatory aCD3 nanoarrays. Nano Lett. 13, 5090–5097 (2013).10.1021/nl4022623 ↗
44. Guasch, J., Muth, C. A., Diemer, J., Riahinezhad, H. & Spatz, J. P. Integrin-assisted T-cell activation on nanostructured hydrogels. Nano Lett. 17, 6110–6116 (2017). This work proposes that the nanoscale arrangement of anti-CD3 and integrin-binding ligands can be strategically engineered to modulate T cell activation.10.1021/acs.nanolett.7b02636 ↗
45. Pinheiro, A. V., Han, D., Shih, W. M. & Yan, H. Challenges and opportunities for structural DNA nanotechnology. Nat. Nanotechnol. 6, 763–772 (2011).10.1038/nnano.2011.187 ↗
46. Teixeira, A. I. et al. Spatial regulation of T-cell signaling by programmed death-ligand 1 on wireframe DNA origami flat sheets. ACS Nano 15, 3441–3452 (2021).10.1021/acsnano.0c10632 ↗
47. Hellmeier, J. et al. DNA origami demonstrate the unique stimulatory power of single pMHCs as T-cell antigens. Biophys. J. 120, 330a (2021).10.1016/j.bpj.2020.11.2077 ↗
48. Cheung, A. S., Zhang, D. K. Y., Koshy, S. T. & Mooney, D. J. Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat. Biotechnol. 36, 160–169 (2018).10.1038/nbt.4047 ↗
49. Fadel, T. R. et al. A carbon nanotube-polymer composite for T-cell therapy. Nat. Nanotechnol. 9, 639–647 (2014).10.1038/nnano.2014.154 ↗
50. Jie, J., Mao, D., Cao, J., Feng, P. & Yang, P. Customized multifunctional peptide hydrogel scaffolds for CAR-T-cell rapid proliferation and solid tumor immunotherapy. ACS Appl. Mater. Interfaces 14, 37514–37527 (2022).10.1021/acsami.2c10727 ↗
51. Lambert, L. H. et al. Improving T cell expansion with a soft touch. Nano Lett. 17, 821–826 (2017).10.1021/acs.nanolett.6b04071 ↗
52. Mandal, S. et al. Polymer-based synthetic dendritic cells for tailoring robust and multifunctional T cell responses. ACS Chem. Biol. 10, 485–492 (2015).10.1021/cb500455g ↗
53. Aramesh, M. et al. Nanoconfinement of microvilli alters gene expression and boosts T cell activation. Proc. Natl Acad. Sci. USA 118, e2107535118 (2021).10.1073/pnas.2107535118 ↗
54. Bhingardive, V. et al. Antibody-functionalized nanowires: a tuner for the activation of T cells. Nano Lett. 21, 4241–4248 (2021).10.1021/acs.nanolett.1c00245 ↗
55. Esmaeili, F. et al. Spiky gold nanoparticles, a nanoscale approach to enhanced ex vivo T-cell activation. ACS Nano 18, 21554–21564 (2024).10.1021/acsnano.4c07306 ↗
56. Lei, K., Kurum, A. & Tang, L. Mechanical immunoengineering of T cells for therapeutic applications. Acc. Chem. Res. 53, 2777–2790 (2020).10.1021/acs.accounts.0c00486 ↗
57. Perica, K. et al. Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. ACS Nano 8, 2252–2260 (2014).10.1021/nn405520d ↗
58. Liu, Z. et al. Nanoscale optomechanical actuators for controlling mechanotransduction in living cells. Nat. Methods 13, 143–146 (2016).10.1038/nmeth.3689 ↗
59. Zheng, Y. et al. Optoregulated force application to cellular receptors using molecular motors. Nat. Commun. 12, 3580 (2021).10.1038/s41467-021-23815-4 ↗
60. Fu, D. et al. Mechanically optimize T cells activation by spiky nanomotors. Front. Bioeng. Biotechnol. 10, 844091 (2022).10.3389/fbioe.2022.844091 ↗
61. Chada, N. C. & Wilson, J. T. Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology. Curr. Opin. Biotechnol. 89, 103179 (2024).10.1016/j.copbio.2024.103179 ↗
62. Belling, J. N. et al. Acoustofluidic sonoporation for gene delivery to human hematopoietic stem and progenitor cells. Proc. Natl Acad. Sci. USA 117, 10976–10982 (2020).10.1073/pnas.1917125117 ↗
63. Sytsma, B. J. et al. Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells. Sci. Rep. 15, 5749 (2025).10.1038/s41598-025-89070-5 ↗
64. Aramesh, M. et al. Enhanced cellular uptake through nanotopography-induced macropinocytosis. Adv. Funct. Mater. 34, 2400487 (2024).10.1002/adfm.202400487 ↗
65. Pan, H. et al. Glycometabolic bioorthogonal chemistry-guided viral transduction for robust human T cell engineering. Adv. Funct. Mater. 29, 1807528 (2019).10.1002/adfm.201807528 ↗
66. Chen, Y. et al. Efficient non-viral CAR-T cell generation via silicon-nanotube-mediated transfection. Mater. Today 63, 8–17 (2023).10.1016/j.mattod.2023.02.009 ↗
67. Shokouhi, A. R. et al. Engineering efficient CAR-T cells via electroactive nanoinjection. Adv. Mat. 35, e2304122 (2023).10.1002/adma.202304122 ↗
68. Tay, A. & Melosh, N. Mechanical stimulation after centrifuge-free nano-electroporative transfection is efficient and maintains long-term T cell functionalities. Small 17, 2103198 (2021).10.1002/smll.202103198 ↗
69. Xiong, R. et al. Fast spatial-selective delivery into live cells. J. Control. Release 266, 198–204 (2017).10.1016/j.jconrel.2017.09.033 ↗
70. Pinto, I. S., Cordeiro, R. A. & Faneca, H. Polymer- and lipid-based gene delivery technology for CAR T cell therapy. J. Control. Release 353, 196–215 (2023).10.1016/j.jconrel.2022.11.038 ↗
71. Selby, L. I., Cortez-Jugo, C. M., Such, G. K. & Johnston, A. P. R. Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles. WIREs Nanomed. Nanobiotechnol. 9, e1452 (2017).10.1002/wnan.1452 ↗
72. Olden, B. R., Cheng, Y., Yu, J. L. & Pun, S. H. Cationic polymers for non-viral gene delivery to human T cells. J. Control. Release 282, 140–147 (2018).10.1016/j.jconrel.2018.02.043 ↗
73. Prazeres, P. H. D. M. et al. Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells. Int. J. Nanomed. 18, 5891–5904 (2023).10.2147/IJN.S424723 ↗
74. Billingsley, M. M. et al. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 20, 1578–1589 (2020).10.1021/acs.nanolett.9b04246 ↗
75. Padilla, M. S. et al. Branched endosomal disruptor (BEND) lipids mediate delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complex for hepatic gene editing and T cell engineering. Nat. Commun. 16, 996 (2025).10.1038/s41467-024-55137-6 ↗
76. Metzloff, A. E. et al. Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy. Adv. Mater. 36, 2313226 (2024). This publication presents lipid nanoparticles conjugated with anti-CD3 and anti-CD28, and encapsulating CAR mRNA, enabling activation and transfection of primary human T cells in a single step.10.1002/adma.202313226 ↗
77. Billingsley, M. M. et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 22, 533–542 (2022).10.1021/acs.nanolett.1c02503 ↗
78. Yee Mon, K. J. et al. Functionalized nanowires for miRNA-mediated therapeutic programming of naïve T cells. Nat. Nanotech. 19, 1190–1202 (2024).10.1038/s41565-024-01649-7 ↗
79. Hamilton, A. G. et al. Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA CAR T cell engineering. Adv. Healthc. Mater. 12, 2301515 (2023).10.1002/adhm.202301515 ↗
80. Chamberlain, C. A. et al. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Mol. Ther. Oncolytics 24, 417–428 (2022).10.1016/j.omto.2022.01.004 ↗
81. Brudno, J. N., Maus, M. V. & Hinrichs, C. S. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA 22, 1924–1935 (2024).10.1001/jama.2024.19462 ↗
82. Wang, L. et al. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors. Cancer Lett. 591, 216871 (2024).10.1016/j.canlet.2024.216871 ↗
83. Zhang, A. Q. et al. Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. Nat. Biomed. Eng. 7, 1113–1128 (2023).10.1038/s41551-023-01048-8 ↗
84. Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446–453 (2020).10.1126/science.aay5967 ↗
85. Yoon, J., Fagan, E., Jeong, M. & Park, J.-H. In situ tumor-infiltrating lymphocyte therapy by local delivery of an mRNA encoding membrane-anchored anti-CD3 single-chain variable fragment. ACS Nano 18, 32401–32420 (2024). This work explores the use of mRNA-loaded lipid nanoparticles in tumours, enabling the in vivo engineering of TAMs and tumour cells to express anti-CD3 and thereby promote in situ engagement of TILs.10.1021/acsnano.4c03518 ↗
86. Stephan, M. T., Moon, J. J., Um, S. H., Bersthteyn, A. & Irvine, D. J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16, 1035–1041 (2010).10.1038/nm.2198 ↗
87. Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707–716 (2018).10.1038/nbt.4181 ↗
88. Luo, Y. et al. IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy. Biomaterials 281, 121341 (2022).10.1016/j.biomaterials.2021.121341 ↗
89. Liu, Y. et al. Cytokine conjugation to enhance T cell therapy. Proc. Natl Acad. Sci. USA 120, e2213222120 (2023).10.1073/pnas.2213222120 ↗
90. Zheng, Y. et al. In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J. Control. Release 172, 426–435 (2013).10.1016/j.jconrel.2013.05.037 ↗
91. Weiss, L. et al. Direct in vivo activation of T cells with nanosized immunofilaments inhibits tumor growth and metastasis. ACS Nano 17, 12101–12117 (2023).10.1021/acsnano.2c11884 ↗
92. Sun, Y. et al. DNA origami–based artificial antigen-presenting cells for adoptive T cell therapy. Sci. Adv. 8, eadd1106 (2022).10.1126/sciadv.add1106 ↗
93. Meyer, R. A. et al. Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small 11, 1519 (2015).10.1002/smll.201402369 ↗
94. Li, X. et al. Enhancing adoptive cell therapy by T cell loading of SHP2 inhibitor nanocrystals before infusion. ACS Nano 16, 10918–10930 (2022).10.1021/acsnano.2c03311 ↗
95. Stephan, M. T., Stephan, S. B., Bak, P., Chen, J. & Irvine, D. J. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials 33, 5776–5787 (2012).10.1016/j.biomaterials.2012.04.029 ↗
96. Siriwon, N. et al. CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Cancer Immunol. Res. 6, 812–824 (2018).10.1158/2326-6066.CIR-17-0502 ↗
97. Chen, Z. et al. Nanoengineered CAR-T biohybrids for solid tumor immunotherapy with microenvironment photothermal-remodeling strategy. Small 17, 2007494 (2021).10.1002/smll.202007494 ↗
98. Zhao, Z. et al. A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer. Nat. Nanotechnol. https://doi.org/10.1038/s41565-025-01924-1 (2025).10.1038/s41565-025-01924-1 ↗
99. Nie, W. et al. Magnetic nanoclusters armed with responsive PD-1 antibody synergistically improved adoptive T-cell therapy for solid tumors. ACS Nano 13, 1469–1478 (2019).10.1021/acsnano.8b07141 ↗
100. Schmid, D. et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat. Commun. 8, 1747 (2017).10.1038/s41467-017-01830-8 ↗